377 results about "Proliferation activity" patented technology

Antibody to human IL-20 protein, a method for generation thereof and cells producing this antibody are disclosed. The antibody of the present invention has specificity to neutralizing hIL-20W-induced CPAE proliferation activity, and is useful for treating IL-20-induced inflammation, such as artheriosclerosis and rheumatoid arthritis.

Antibody to human IL-20 protein, a method for generation thereof and cells producing this antibody are disclosed. The antibody of the present invention has specificity to neutralizing hIL-20W-induced CPAE proliferation activity, and is useful for treating IL-20-induced inflammation, such as artheriosclerosis and rheumatoid arthritis.

The present invention is related to the preparation and pharmaceutical use of novel benzamide derivatives as defined in the specification of formula (I) as histone deacetylase inhibitors (HDACI), their preparations and the methods of using these compounds or their pharmaceutically acceptable salt in the treatment of cell proliferative diseases, e.g. cancer and psoriasis

The invention discloses a type of amino acid modified curcumin, a synthesis method thereof, and an application thereof. According to the invention, structural modification is carried out upon curcumin by using natural amino acid, such that 1-(4-hydroxy-3-methoxyphenyl)-7-(4-oxyacetyl amino carbobenzoxy-3-methoxyphenyl)-1,6-heptadiene-3,5-diketone which is represented by a general formula (I) is obtained. With an MTT method, evaluation is carried out upon the compound represented by the general formula (I) in the inhabitance of proliferation activities of four cells which are K562, H22, HL60 and S180. IC50 values of the compound represented by the general formula (I) in inhibiting the proliferations of the four tumor cells are calculated. As a result of experiments, with the compound represented by the general formula (I), proliferations of tumor cells can be substantially inhibited. The compound has excellent anti-tumor activity, and can be prepared into anti-tumor medicines.

The invention discloses a cryopreservation solution for preserving congenital intrathoracic kidney (CIK) cells and application thereof. The cryopreservation solution for preserving the CIK cells is prepared according to the following methods: adding dimethyl sulfoxide and dextran into a lymphocyte serum-free medium, so that the volume percent content of the dimethyl sulfoxide is 5-15 percent, and the volume percent content of the dextran is 5-15 percent. Compared with the cells before cryopreservation, the cells cryopreserved by employing the cryopreservation solution have the following advantages: (1) the cellular morphology does not have obvious difference; (2) immunophenotype (CD3+CD56+CD8+) does not have obvious difference; and (3) the cell proliferation activity and cell killing activity do not have obvious difference.

The invention relates to the technical field of medicine, in particular to a new benzoxanthone type compound and an application thereof in pharmacy. Benzoxanthone type derivatives are one type of topoisomerase I inhibitors in new structure, which are found in recent years, and have obvious cell proliferation activity. The invention provides the new benzoxanthone type compound and pharmaceutical salts thereof, and the structure of the compound is as shown in the general formula (I). The invention further provides the application of the benzoxanthone type compound and the pharmaceutical salts thereof in the preparation of the topoisomerase inhibitors, anti-tumor medicaments, antifungal medicaments, antiviral medicaments, anti-hypertensive medicaments or anti-thrombotic medicaments.

The invention provides proliferative response indicator cell having a vertebrate cell having a luciferase encoding nucleic acid and a heterologous proliferation factor receptor encoding nucleic acid, wherein each of the encoding nucleic acids are operationally linked to expression elements for co-expression of a luciferase polypeptide and a heterologous proliferation factor receptor. The invention also provides a method of determining a cell proliferative response to a proliferation factor. The method includes: (a) contacting a vertebrate cell expressing luciferase and a proliferation factor receptor with a proliferation factor for sufficient time for the proliferation factor to bind to the proliferation factor receptor; (b) culturing the contacted cell expressing luciferase for at least one generation, and (c) measuring the amount of light emission, wherein the luciferase expression is driven from a promoter non-responsive to the proliferation factor and the light emission directly correlates with proliferation factor-mediated cell proliferation. The proliferation factor can be a growth factor, a cytokine or a hormone or an agonist or antagonist thereof. The methods of the invention additionally include determining the effect of an inhibitor of the proliferation factor. Cells used in the method are contacted with a proliferation factor in the presence of a sample suspected of containing an inhibitor of the proliferation factor. The inhibitor can be neutralizing antibody, or binding fragment thereof, to the proliferation factor. The methods of the invention also are applicable as an indicator of cell health or viability. The invention further provides a diagnostic system. The diagnostic system includes a plurality of different vertebrate cell lines each encoding a luciferase gene and a different proliferation factor receptor, the luciferase gene being operationally linked to a promoter non-responsive to a proliferation factor bound by the proliferation factor receptor, wherein light emission from each of the different cell lines being characterized as directly correlating with proliferation factor-mediated cell proliferation.

The invention discloses a tissue repair material which comprises an SIS (small intestinal submucosa) and an NGF (nerve growth factor). When the NGF is individually used or simply mixed with the SIS in use, the NGF is rapidly inactivated and is unfavorable for wound repair. However, after the composite material is prepared with the NGF and the SIS according to the specific method, the action time of the NGF can be effectively prolonged, the cell proliferation activity of the NGF-SIS composite material is remarkably enhanced as compared with that of the individually used SIS, and the NGF-SIS composite material plays a role in synergy.

This invention relates to producing of high efficiency immune cell group and method of its using to tumor preventing, it belongs to biotechnology field. Dendritic cell is induced by oligonucleotide and cytokine, cell is induced and wounded by the cytokine, then dendritic cell and wounded cell are mixed with certain ratio to get new kind cell group that cultured by immune effect cell group dendritic that induced by oligonucleotide and the wounded cell. Compared to cell group cultured by wounded cell and dendritic cell, the proliferation activity is stronger. The cell poisonous activity is higher than the wounded cell. The oligonucleotide can be artificially synthesized. Immune cell group that anti cancer activity is higher than the wounded cell can also be induced to patient that operation opportunity is gone and tumor antigen is hard to get. It can be used to self-body tumor curing, chemical treatment and assistant curing to radiotherapy.

The invention discloses a synthesis and medical application of pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound. The compound belongs to a novel-structure compound. The synthesis method is high in operating safety, mild in reaction condition and suitable for industrial production. The activity and the selectivity of BTK kinase and the in-vitro proliferation activity of a leukemia cell line are test, it is verified that the compound has the selective and irreversible inhibition effect on the BTK kinase, and has the different-degree inhibition effect on leukemia cells. According to measurement, the compound also has the good anti-arthritic activity on a collagen-induced arthritis (rCIA) model. The pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound can be used for preparing medicine for treating arthritis and leukemia.

The invention discloses an in-vitro efficient culture method for muscle stem cells, and a universal muscle stem cell in-vitro culture kit comprising a muscular tissue digestive enzyme, a muscle cell culture medium and a cell culture plate coating solution. The in-vitro culture method is characterized by being capable of rapidly acquiring and amplifying muscle stem cells, maintaining regeneration activity of the muscle stem cells and culturing stem cells which are stable in cell morphology, capable of stably expressing a muscle stem cell marker Pax7 and high in proliferation activity. By adopting the technique disclosed by the invention, relatively pure mouse muscle stem cells can be obtained, and the muscle stem cell marker Pax7 can be expressed. In addition, the cells also express muscle system transcription factors Myf-5 and MyoD; after the cells are differentiated into myotubes, a distinctive muscle structure protein Desmin can be stably expressed.

The invention belongs to the technical field of biological genetic engineering, and discloses technology for constructing and expressing porcine alpha interferon (PoIFN-alpha) and interleukin 2 (PoIL-2) chimeric gene and quickly renaturing and purifying expression protein. The technology constructs mature peptide genes of PoIFN-alpha and PoIL-2 into PoIFN-alpha-linker-PoIL-2 chimeric gene through a genetic flexible linker (linker) (G4S)3 and clones the chimeric gene into a pGEM-T Easy vector by adopting an overlap extension PCR method, and subclones the chimeric gene into a pQE-30 expression vector for prokaryotic expression. The recombinant fusion protein (rPoIFN-alpha-linker-PoIL-2) can be quickly renatured and purified through urea modification, renaturation by low concentration protein renaturing solution, PBS solution dialysis and other steps. The purified rPoIFN-alpha-linker-PoIL-2 fusion protein has proliferation activity for inhibiting vesicular stomatitis virus (VSV) on a cell, is used for prevention and treatment of porcine virosis as a main ingredient of an antivirus preparation, and has high efficiency, broad spectrum, safety and low price.

A method for preparing primary cell dental pulp stem construction and method of dental pulp stem cell library, the use of thermostatic shaker at specific temperature and speed conditions, can be in a few minutes after digestion, to extract enough has good biological activity of dental pulp stem cells, which can shorten the primary dental pulp stem cells generation of extraction time, save time and cost, large scale production can be obtained at the same time, plenty of pulp stem cells, can meet the requirements of dental pulp stem cells in stem cell library and later stem cells for clinical treatment and regenerative medicine research needs, and the pulp tissue under conventional semi digested 30min or full digestion 1H control group compared to the amount of DPSCs had no significant difference, but the cell proliferation activity was significantly higher than the control group. Therefore, this method can be carried out quickly in batches in the construction of DPSCs library, which shortens the time of DPSCs primary extraction, saves time and cost, and is suitable for large-scale production.

The invention discloses a mechanical environment culture method for improving the proliferation activity of chondrocytes and maintaining phenotype of chondrocytes. The invention comprises the following steps: step 1, carrying out separation, culture and identification of chondrocytes; 2, inoculating the chondrocytes into a culture apparatus, loading the chondrocytes during the culture process, andculturing the chondrocyte in a mechanical environment so that the chondrocytes are mechanically stimulated. Under culture in mechanical environment, the proliferation of chondrocytes is improved, andco-cultured cells is promoted to have a good cartilage phenotype, which can quickly and effectively provide excellent seed cells for cartilage tissue engineering, and solve the clinical and practicalneeds of tissue engineering cartilage seed cells.

The invention provides an aromatic heterocyclic amide substituted diarylurea compound, a preparation method and application thereof. The structural formula of the compound is shown as the specification, wherein Ar is a pyridine heterocycle containing pivaloyl amino or methylamine carbonyl, R1 and R2 are trifluoromethyl, trifluoromethoxy or halogen, R2 can also be alkoxy with a tertiary amine group substituted end and a carbon atom number of 2-3, and the alkoxy is connected to the para-position of urea through the O atom. The compound can be prepared by three-step organic synthesis reaction, and the method has the advantages of easy operation of the reaction process, easily available raw materials, mild reaction conditions, cheap reagents and the like, and is suitable for large-scale production by pharmaceutical enterprises. The compound has good inhibitory activity on VEGFR-2 kinase, also can inhibit the proliferation activity of tumor cells, and can be used for preparation of antitumor drugs and VEGFR-2 kinase activity inhibition drugs, thus having good application prospects and scientific research value.

The invention relates to application of compounds and salt thereof, and particularly relates to application of matrine compounds and salt thereof in preparation of anti-hepatic fibrosis and anti-liver cancer medicaments. The compounds have the advantages of remarkably inhibiting the proliferation of hepatoma cell lines Hep-G2, Hun-7, MHCC-97L, SMMC-7721 and Hep-3B and proliferation activities of fibroblast BJ, human hepatic stellate cells LX-2 and hepatic stellate cells HSC-T6, and can be used for preparing medicaments for treating hepatic fibrosis and liver cancer.

The invention discloses an immune cell cryopreservation liquid and a cryopreservation method. The cryopreservation liquid comprises a basic culture medium and additives. The additives include, by final concentration, 1-5 g / mL of trehalose, 3-6 v / v% of propylene glycol, 3-5 v / v% of acetamide, 5-10 v / v% of dextran, 1-3 g / mL of hydroxyethyl starch, 0.5-1.5 g / mL of glucose, 50-150 U / mL of heparin sodium, 5-15 mg / mL of herba phyllanthi urinariae extract and 0.5-1.5 mg / mL of bacillus Calmette-Guerin composite polysaccharides. The cryopreservation liquid is simple in formulation, interaction and synergistic effects of the components are achieved, endothelial progenitor cell cryopreservation effects can be evidently improved by the adoption of the cryopreservation method, insusceptibility of post-reviving cell proliferation activity can be guaranteed, and it is guaranteed that intracellular moisture of cells close to a freezing point is free of crystallization.

The invention discloses novel 4-substituted anilinoquinazoline derivatives or pharmaceutically acceptable salts thereof, or polymorphic substances, solvates or stereomers of the 4-substituted anilinoquinazoline derivatives, and a preparation method and application thereof. The 4-substituted anilinoquinazoline compounds have favorable inhibition activities for EGFR and VEGFR-2 in a biological test and have obvious effects in an in-vitro anti-human tumor cell proliferation activity test.

The invention discloses an anti-aging cosmetic composition. The composition comprises the following components in parts by weight: 1-15 parts of plant extract, 2.55-7 parts of emulsifier, 4-26 parts of emollient, 2.5-20 parts of humectant, 0.1-0.3 part of dipotassium glycyrrhizinate, 0.1-2 parts of silica, 0.03-0.07 part of potassium hydroxide, 0.1-0.2 part of thickening agent, 0.05-2 parts of antioxidant, 0.201-1.01 parts of preservative and 40-75 parts of water, wherein the plant extract is mixed liquid of a liquorice extract and an American ginseng extract. According to the anti-aging cosmetic composition, the mixed liquid of liquorice extract and American ginseng extract is applied to the anti-aging cosmetic, the proliferation activity of skin cells can be effectively improved, and the symptoms of skin aging can be reduced.

The invention belongs to the field of biology, and particularly relates to a nucleotide sequence of a recombinant fibronectin mutant and application of the recombinant fibronectin mutant. According tothe recombinant fibronectin mutant provided by the invention, a structural domain for promoting cell adhesion and cell proliferation on fibronectin is selected, the nucleotide sequence for coding therecombinant fibronectin mutant is designed by utilizing a translation pause theory, and under the condition of unchanging an amino acid sequence of the recombinant fibronectin, the recombinant fibronectin is obtained by replacing a codon with a higher translation speed in the last 20 codons of the recombinant fibronectin with a codon with a lower translation speed. The recombinant fibronectin mutant provided by the invention is simple in purification process and can promote cell proliferation activity and adhesion activity.

The invention belongs to the technical field of medicament synthesis and in particular relates to synthesis of tetrahydroisoquinoline compounds and initial application of the tetrahydroisoquinoline compounds in inhibiting tumor cell proliferation. Through the modification of a structure of natural (-)-alpha-(1R,9S)-narcotine, a series of novel tetrahydroisoquinoline compounds (I) are synthesized. Through the screening of anti-tumor activity in vitro, the novel tetrahydroisoquinoline compounds have remarkable effect of inhibiting the tumor cell proliferation activity and can be further developed into a novel anti-tumor medicament.

The invention discloses a recombinant human endostatin protein with different amino acid structures, a method for preparing the recombinant human endostatin protein and application thereof. Amino acid sequences of a recombinant human endostatin protein 1 are shown as SEQ ID NO.1, and amino acid sequences of a recombinant human endostatin protein 2 are shown as SEQ ID NO.2. The recombinant human endostatin protein, the method and the application have the advantages that the two types of recombinant proteins are active in the aspects of inhibiting the proliferation activity of vascular endothelial cells under the induction actions of basic fibroblast growth factors (bFGF) and inhibiting the angiogenesis activity of chick chorioallantoic membranes (CAM) and are easy to enter the vascular endothelial cells and vascular endothelial cells of the chick chorioallantoic membranes, and transmembrane effects of the recombinant human endostatin protein and the structural stability of N ends can be obviously improved; effects of directly inhibiting tumor cell growth can be realized, effects of inhibiting generation of neonatal vascular endothelial cells can be effectively realized, and the recombinant human endostatin protein can be used for treating various diseases, including solid tumor, retinal diseases due to diabetes mellitus and rheumatoid arthritis, due to angiogenesis.

The invention relates to the field of a preparation method and application of a traditional Chinese medicine effective component and in particular relates to a preparation method of rhizoma polygonatipolysaccharide and application of the rhizoma polygonati polysaccharide to the preparation of an immunological enhancement medicine. The rhizoma polygonati polysaccharide is obtained by processing raw rhizoma polygonati, extracting and separating; when an extraction method provided by the invention is adopted, the extraction rate of the rhizoma polygonati polysaccharide is high and the content oftotal polysaccharide is high; the proliferation activity of the rhizoma polygonati polysaccharide on normal mouse spleen cells is improved; cyclophosphamide induced spleen and thymus gland index of mice with low immunity also can be improved; the in-vitro proliferation capability of spleen and thymus gland cells under the stimulation of concanavalin A is enhanced; the phagocytic function of macrophage of the mice with the low immunity and the capability of secreting IL-6 and TNF-alpha are enhanced; the rhizoma polygonati polysaccharide has actual application value in the aspect of treatment of diseases including immunodeficiency diseases, tumors and the like.

An agent which comprises, as an active ingredient, a radiolabeled compound as represented by the following formula or a pharmaceutically acceptable salt thereof: wherein R1 denotes hydrogen, or a linear- or branched-chain alkyl group having 1-8 carbon atoms, R2 denotes hydrogen, hydroxyl or a halogen substituent, R3 denotes hydrogen or fluorine substituent, R4 denotes oxygen, sulfur, or a methylene substituent, and R denotes a radioactive halogen substituent. The agent is stable in vivo, and either stays in cells or is incorporated in DNA, thus serving for diagnosis of tissue proliferation activity or treatment of proliferative disease.

An agent which comprises, as an active ingredient, a radiolabeled compound as represented by the following formula or a pharmaceutically acceptable salt thereof:wherein R1 denotes hydrogen, or a linear- or branched-chain alkyl group having 1–8 carbon atoms, R2 denotes hydrogen, hydroxyl or a halogen substituent, R3 denotes hydrogen or fluorine substituent, R4 denotes oxygen, sulfur, or a methylene substituent, and R5 denotes a radioactive halogen substituent.The agent is stable in vivo, and either stays in cells or is incorporated in DNA, thus serving for diagnosis of tissue proliferation activity or treatment of proliferative disease.

The invention relates to the technical field of a horse placenta extract and a pharmaceutical application thereof, specifically to a horse placenta water-soluble protein extract with bioactivity, a preparation method and an application thereof. According to the present invention, during an extraction process, a phosphate buffer solution with a pH value close to a physiological pH value and an osmotic pressure close to a physiological osmotic pressure is adopted as an extraction solvent so as to maintain activity of active substances in a horse placenta to the maximal degree; with the horse placenta extract, activity of normal lymphocytes can be significantly enhanced, proliferation activity of T-lymphocytes and B-lymphocytes induced by ConA and LPS can be significantly inhibited, and killing activity of NK cells on PC-3 cancer cells can be significantly enhanced, such that adjustment effects are provided for immune functions to a certain degree; and with the horse placenta extract, oxidative damage of skin fibroblasts due to H2O2 can be significantly inhibited, cell viability can be improved, MDA content in cells can be reduced, enzyme activities of SOD and GPx can be improved, apoptosis rate can be reduced, and DNA damage can be inhibited, such that a certain protection effect is provided for oxidative damage.

The present invention relates to protein modulators, especially modulators of kinesin bioactivities. The present invention provides methods for screening protein modulators, e.g., kinesin modulators that bind to a region of a kinesin and / or that modulate kinesin bioactivities. The present invention also provide methods and compositions for treatment of disorders mediated by abnormal cellular proliferation activities.